Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBluecross Idaho gMG Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy MP 5.01.539

    Biological Treatments for Refractory Myasthenia Gravis

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.539 alerts

    Get alerted when Policy MP 5.01.539 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for specified biologic treatments used to treat generalized myasthenia gravis (gMG). Coverage applies to eligible individuals when the drug-specific clinical, laboratory, prior-treatment, safety, and response criteria are met.

    Policy Summary
    PayerBluecross Idaho
    PolicyBiological Treatments for Refractory Myasthenia Gravis
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with product-specific clinical criteria, prior-treatment history, safety documentation, and continuation response measures.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Subcutaneous efgartigimod and rozanolixizumab were added as therapies that may be medically necessary for initial or continued treatment of refractory myasthenia gravis when stated criteria are met.

    The policy title was changed from Biological Treatments for Anti-Acetylcholine Receptor Antibody Positive Refractory Myasthenia Gravis to Biological Treatments for Refractory Myasthenia Gravis.

    The policy was updated to clarify prior therapies required for Rystiggo.

    The policy history states that policy statements were revised effective January 1, 2027.

    The policy added criteria for Imaavy (nipocalimab-aahu) and expanded biological-treatment criteria for refractory myasthenia gravis.

    For Vyvgart initial treatment in generalized myasthenia gravis, the policy expanded the antibody list and added triple-seronegative disease documentation.

    The policy clarified the prior therapies required for Rystiggo.

    5Biologic treatment options with gMG criteria
    6 monthsInitial authorization period
    12 monthsReauthorization period
    2 pointsRequired MG-ADL improvement for most continuation requests
    Triple-seronegativeVyvgart initial-treatment disease category added

    Drug-Specific Coverage Criteria

    Epysqli initial therapy

    Eculizumab-aagh is medically necessary when all of the following are met.

    Epysqli initial treatment

    • Eligibility: Age at least 18; generalized myasthenia gravis with MGFA class II-IV disease; anti-AChR antibody positive; and MG-ADL score at least 6.MG-ADL >= 6
    • Prior treatment: Inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy, either in combination or as monotherapy.

      Examples include pyridostigmine, neostigmine, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide.

    • Safety and administration requirements: Meningococcal vaccination at least 2 weeks before initiation unless treatment cannot be delayed; the prescribing physician is enrolled in the appropriate REMS program; and the individual is not using eculizumab in combination with maintenance immunoglobulin treatment, nipocalimab-aahu, ravulizumab-cwvz, efgartigimod-alfa, rozanolixizumab-noli, zilucoplan, or rituximab.

    Epysqli continuation therapy

    Eculizumab continuation is medically necessary when all of the following are met.

    Epysqli continuation treatment: The individual continues to meet the initial treatment criteria and has a decrease of 2 points in MG-ADL total score from the pretreatment baseline value.MG-ADL decrease >= 2 points

    Reauthorization is for 12 months.

    Ultomiris initial therapy

    Ravulizumab-cwvz is medically necessary when all of the following are met.

    Ultomiris initial treatment: Age at least 18; generalized myasthenia gravis with MGFA class II-IV disease; anti-AChR antibody positive; MG-ADL score at least 6; inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy, either in combination or as monotherapy; meningococcal vaccination at least 2 weeks before initiation unless treatment cannot be delayed; the prescribing physician is enrolled in the appropriate REMS program; and the individual is not using ravulizumab in combination with maintenance immunoglobulin treatment, nipocalimab-aahu, eculizumab, efgartigimod-alfa, rozanolixizumab-noli, zilucoplan, or rituximab.MG-ADL >= 6

    Initial authorization is for 6 months.

    Ultomiris continuation therapy

    Ravulizumab-cwvz continuation is medically necessary when all of the following are met.

    Ultomiris continuation treatment: The individual continues to meet the initial treatment criteria and has a decrease of 2 points in MG-ADL total score from the pretreatment baseline value.MG-ADL decrease >= 2 points

    Reauthorization is for 12 months.

    Vyvgart initial therapy

    Efgartigimod alfa-fcab or efgartigimod alfa with hyaluronidase-gvfc is medically necessary when all of the following are met.

    Vyvgart or Vyvgart Hytrulo initial treatment

    • Eligibility: Age at least 18; generalized myasthenia gravis with MGFA class II-IV disease; and MG-ADL score at least 5.MG-ADL >= 5
    • ONE of

      • Anti-AChR antibody positive, anti-MuSK antibody positive, or anti-LRP4 antibody positive.
      • Triple-seronegative disease confirmed by characteristic electrodiagnostic findings using repetitive nerve stimulation or single-fiber electromyography.
    • ONE of the applicable prior-treatment pathways

    Vyvgart continuation therapy

    Efgartigimod continuation is medically necessary when all of the following are met.

    Vyvgart or Vyvgart Hytrulo continuation treatment: The individual continues to meet the initial treatment criteria and has a decrease of 2 points in MG-ADL total score from the pretreatment baseline value.MG-ADL decrease >= 2 points

    Reauthorization is for 12 months.

    Imaavy initial therapy

    Nipocalimab-aahu is medically necessary when all of the following are met.

    Imaavy initial treatment

    • Eligibility: Age at least 12; generalized myasthenia gravis with MGFA class II-IVa disease; anti-AChR or anti-MuSK antibody positive; and MG-ADL score at least 6.MG-ADL >= 6
    • ONE of the applicable prior-treatment pathways

      • For anti-AChR-positive disease: inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy, either in combination or as monotherapy.
      • For anti-MuSK-positive disease: inadequate response, intolerance, or contraindication to at least one immunosuppressive therapy.

    Imaavy continuation therapy

    Nipocalimab continuation is medically necessary when all of the following are met.

    Imaavy continuation treatment: The individual continues to meet the initial treatment criteria, has a reduction in signs or symptoms that impact daily function, and has a decrease of 2 points in MG-ADL total score from the pretreatment baseline value.MG-ADL decrease >= 2 points

    Reauthorization is for 12 months.

    Rystiggo initial therapy

    Rozanolixizumab-noli is medically necessary when all of the following are met.

    Rystiggo initial treatment

    • Eligibility: Age at least 18; generalized myasthenia gravis with MGFA class II-IVa disease; anti-AChR or anti-MuSK antibody positive; and MG-ADL score at least 3 with at least 3 points from non-ocular symptoms.MG-ADL >= 3; non-ocular MG-ADL points >= 3
    • Laboratory requirement: IgG level at least 5.5 g/L.IgG >= 5.5 g/L
    • ONE of the applicable prior-treatment pathways

      • For anti-AChR-positive disease: inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy, either in combination or as monotherapy.

    Rystiggo continuation therapy

    Rozanolixizumab continuation is medically necessary when all of the following are met.

    Rystiggo continuation treatment: The individual continues to meet the initial treatment criteria and has a decrease of 2 points in MG-ADL total score from the pretreatment baseline value.MG-ADL decrease >= 2 points

    Reauthorization is for 12 months.

    Coverage requires that the requested biologic not be used with maintenance immunoglobulin treatment or another product specifically prohibited for that therapy. Prohibited combinations may include other covered biologics, zilucoplan, or rituximab, as identified in the drug-specific criteria.

    Rozanolixizumab-noli is considered investigational for all indications other than generalized myasthenia gravis (gMG).

    Coding and Clinical Thresholds

    CPTHCPCS
    Q5151Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg
    Q5152Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg
    HCPCSHCPCS
    J1299Injection, eculizumab, 2 mg
    J1303Injection, ravulizumab-cwvz, 10 mg
    J9256Injection, nipocalimab-aahu, 3 mg
    J9332Injection, efgartigimod alfa-fcab, 2 mg
    J9333Injection, rozanolixizumab-noli, 1 mg
    J9334Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
    ICD10ICD-10
    G70.00Myasthenia gravis without (acute) exacerbation
    G70.01Myasthenia gravis with (acute) exacerbation
    ICD10 PCSICD-10
    XW033C6Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6
    XW043C6Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6
    Place of Servicemixed
    1Pharmacy Outpatient, physician office, infusion clinic or
    MG-ADL threshold
    Eculizumab and ravulizumabMG-ADL total score ≥6
    Eculizumab productEpysqli (eculizumab-aagh)
    Ravulizumab productUltomiris (ravulizumab-cwvz)
    MG-ADL threshold
    Efgartigimod productsVyvgart and Vyvgart Hytrulo
    MG-ADL thresholdTotal score ≥5

    Authorization and Documentation Requirements

    Prior Authorization

    Policy and Related Drug Review

    Refer to Blue Cross of Idaho Medical Policy 5.01.500, Preferred Medical Drugs, and Policy 5.01.502, Medical Drugs Not Eligible for Reimbursement, for additional medical-benefit coverage information. Epysqli, Ultomiris, Vyvgart/Vyvgart Hytrulo, Imaavy, and Rystiggo may be considered medically necessary for generalized myasthenia gravis only when the applicable criteria are documented.

    • Applies to eculizumab-aagh, ravulizumab-cwvz, efgartigimod alfa-fcab, efgartigimod alfa/hyaluronidase-gvfc, nipocalimab-aahu, and rozanolixizumab-noli.
    Documentation Required

    Epysqli Initial Authorization

    Obtain prior authorization for Epysqli (eculizumab-aagh) initial treatment and submit documentation supporting all clinical requirements. Initial authorization is limited to 6 months.

    • Age ≥18 years.
    • Generalized myasthenia gravis, MGFA class II–IV; anti-AChR antibody positive; MG-ADL score ≥6.

    Policy Background

    For continued treatment, the individual must continue to meet the applicable initial criteria and demonstrate a clinically meaningful response, generally shown by a 2-point decrease in MG-ADL from the pretreatment baseline.

    Clinical Definitions and Abbreviations

    MGFA classification
    Classification systemMyasthenia Gravis Foundation of America (MGFA) clinical classification
    Eculizumab, ravulizumab, and efgartigimodMGFA classes II to IV
    Nipocalimab and rozanolixizumabMGFA classes II to IVa
    MG-ADL
    Full nameMyasthenia Gravis Activities of Daily Living total score
    PurposeDocuments functional impairment in generalized myasthenia gravis
    Continuation useMeasures treatment response from pretreatment baseline

    Initial Biologic Authorization

    Initial biologic authorization

    Initial therapy is medically necessary only when the applicable product-specific criteria are satisfied.

    Product-specific initial authorization: Meet the applicable age, MGFA disease-classification, antibody or electrodiagnostic, MG-ADL, prior-treatment, safety, and prohibited-combination requirements for the requested product.Varies by product

    Initial authorization is for 6 months for the products described in this policy.

    Continuation Authorization

    Biologic continuation criteria

    Continuation is medically necessary when all of the following are met.

    Biologic continuation: The individual continues to meet the applicable initial treatment criteria and has documented clinical response, including a decrease of 2 points in MG-ADL total score from the pretreatment baseline value. For nipocalimab-aahu, also document a reduction in signs or symptoms that impact daily function.MG-ADL decrease >= 2 points

    Reauthorization is generally for 12 months.

    Required Prior Treatment

    StepClinical pathwayRequired prior therapyCoverage requirement
    1
    Anti-AChR, anti-LRP4, or triple-seronegative disease
    An acetylcholinesterase inhibitor and at least one immunosuppressive therapy, either in combination or as monotherapy
    Inadequate response, intolerance, or contraindication to the required therapy. Examples include pyridostigmine or neostigmine plus therapies such as azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide.
    1
    Anti-MuSK disease
    At least one immunosuppressive therapy
    Inadequate response, intolerance, or contraindication to the required therapy.
    StepAntibody statusRequired prior therapyCoverage requirement
    1
    Anti-AChR antibody positive
    An acetylcholinesterase inhibitor and at least one immunosuppressive therapy, either in combination or as monotherapy
    Inadequate response, intolerance, or contraindication to both required therapy classes.
    1
    Anti-MuSK antibody positive
    At least one immunosuppressive therapy
    Inadequate response, intolerance, or contraindication to the required therapy.

    Administration and Place of Service

    Note

    Provide IV infusion and post-infusion monitoring

    Administer eculizumab and ravulizumab-cwvz only by intravenous infusion, not IV push or bolus. Monitor the individual for at least 1 hour after completion for infusion-related reactions.

    Billing Rule

    Use an applicable place of service

    The listed place of service includes pharmacy outpatient, physician office, and infusion clinic settings. Report the setting that matches where the service is provided.

    Policy Summary
    PayerBluecross Idaho
    PolicyBiological Treatments for Refractory Myasthenia Gravis
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with product-specific clinical criteria, prior-treatment history, safety documentation, and continuation response measures.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Documentation RequirementsPolicy BackgroundClinical Definitions and AbbreviationsInitial Biologic AuthorizationContinuation AuthorizationRequired Prior TreatmentAdministration and Place of Service
    For anti-AChR-positive, anti-LRP4-positive, or triple-seronegative disease: inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy, either in combination or as monotherapy.
  1. For anti-MuSK-positive disease: inadequate response, intolerance, or contraindication to at least one immunosuppressive therapy.
  2. Combination therapy restriction: The individual is not using efgartigimod alfa-fcab or efgartigimod alfa with hyaluronidase-gvfc in combination with maintenance immunoglobulin treatment, eculizumab, nipocalimab-aahu, ravulizumab-cwvz, rozanolixizumab-noli, zilucoplan, or rituximab.
  3. Combination therapy restriction:
    The individual is not using nipocalimab-aahu in combination with maintenance immunoglobulin treatment, eculizumab, ravulizumab-cwvz, efgartigimod-alfa, rozanolixizumab-noli, zilucoplan, or rituximab.
  4. For anti-MuSK-positive disease: inadequate response, intolerance, or contraindication to at least one immunosuppressive therapy.
  5. Combination therapy restriction: The individual is not using rozanolixizumab-noli in combination with maintenance immunoglobulin treatment, eculizumab, efgartigimod alfa-fcab, nipocalimab-aahu, ravulizumab-cwvz, zilucoplan, or rituximab.
  6. Disease classification
    MGFA class II to IV
    MG-ADL threshold
    ProductImaavy (nipocalimab-aahu)
    MG-ADL thresholdScore of at least 6
    Applicable disease classMGFA class II to IVa
    MG-ADL threshold
    ProductRystiggo (rozanolixizumab-noli)
    MG-ADL thresholdMG-ADL total score ≥3
    Non-ocular symptomsAt least 3 points must come from non-ocular symptoms
    Continuation response
    Continuation requirementDecrease of 2 points in MG-ADL total score from pretreatment baseline
    Applies toEculizumab, ravulizumab, efgartigimod, nipocalimab, and rozanolixizumab
    Nipocalimab continuationAlso requires reduced signs or symptoms affecting daily function
    IgG threshold
    ProductRystiggo (rozanolixizumab-noli)
    IgG thresholdIgG level ≥5.5 g/L
    TimingRequired for initial treatment authorization
  7. Inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy, used in combination or as monotherapy.
  8. Meningococcal vaccination ≥2 weeks before treatment unless treatment cannot be delayed; prescribing physician enrolled in the appropriate REMS program.
  9. Do not combine with maintenance immunoglobulin, nipocalimab-aahu, ravulizumab-cwvz, efgartigimod-alfa, rozanolixizumab-noli, zilucoplan, or rituximab.
  10. Documentation Required

    Ultomiris Initial Authorization

    Obtain prior authorization for Ultomiris (ravulizumab-cwvz) initial treatment and submit documentation supporting all clinical requirements. Initial authorization is limited to 6 months.

    • Age ≥18 years.
    • Generalized myasthenia gravis, MGFA class II–IV; anti-AChR antibody positive; MG-ADL score ≥6.
    • Inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy, used in combination or as monotherapy.
    • Meningococcal vaccination ≥2 weeks before treatment unless treatment cannot be delayed; prescribing physician enrolled in the appropriate REMS program.
    • Do not combine with maintenance immunoglobulin, nipocalimab-aahu, eculizumab, efgartigimod-alfa, rozanolixizumab-noli, zilucoplan, or rituximab.
    Documentation Required

    Vyvgart Initial Authorization

    Obtain prior authorization for Vyvgart or Vyvgart Hytrulo initial treatment and document the applicable serologic or electrodiagnostic findings, disease severity, treatment history, and prohibited combinations.

    • Age ≥18 years and gMG with MGFA class II–IV disease; MG-ADL score ≥5.
    • Document anti-AChR, anti-MuSK, or anti-LRP4 antibody positivity, or triple-seronegative disease confirmed by characteristic RNS or single-fiber electromyography.
    • For anti-AChR, anti-LRP4, or triple-seronegative disease: inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy.
    • For anti-MuSK disease: inadequate response, intolerance, or contraindication to at least one immunosuppressive therapy.
    • Do not combine either product with maintenance immunoglobulin, eculizumab, nipocalimab-aahu, ravulizumab-cwvz, rozanolixizumab-noli, zilucoplan, or rituximab.
    Documentation Required

    Imaavy Initial Authorization

    Obtain prior authorization for Imaavy (nipocalimab-aahu) initial treatment and submit documentation supporting age, MGFA class, antibody status, MG-ADL impairment, prior therapy, and prohibited combinations. Initial authorization is limited to 6 months.

    • Age ≥12 years; gMG with MGFA class II–IVa disease; MG-ADL score ≥6.
    • Document positive anti-AChR or anti-MuSK antibody testing.
    • For anti-AChR disease: inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy.
    • For anti-MuSK disease: inadequate response, intolerance, or contraindication to at least one immunosuppressive therapy.
    • Do not combine with maintenance immunoglobulin, eculizumab, ravulizumab-cwvz, efgartigimod-alfa, rozanolixizumab-noli, zilucoplan, or rituximab.
    Documentation Required

    Rystiggo Initial Authorization

    Obtain prior authorization for Rystiggo (rozanolixizumab-noli) initial treatment and document the required disease characteristics, IgG level, prior therapies, and prohibited combinations. Initial authorization is limited to 6 months.

    • Age ≥18 years; gMG with MGFA class II–IVa disease; anti-AChR or anti-MuSK antibody positive.
    • MG-ADL score ≥3, including at least 3 points from non-ocular symptoms.
    • IgG level ≥5.5 g/L.
    • For anti-AChR disease: inadequate response, intolerance, or contraindication to an acetylcholinesterase inhibitor and at least one immunosuppressive therapy.
    • For anti-MuSK disease: inadequate response, intolerance, or contraindication to at least one immunosuppressive therapy.
    • Do not combine with maintenance immunoglobulin, eculizumab, efgartigimod alfa-fcab, nipocalimab-aahu, ravulizumab-cwvz, zilucoplan, or rituximab.
    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the covered biologic treatments addressed by this policy. The policy history reflects adoption and revisions for eculizumab, ravulizumab, efgartigimod, rozanolixizumab, Imaavy, and updated Vyvgart criteria; current applicability is governed by the stated criteria effective January 1, 2027.

    • Current policy review: September 24, 2026; effective date: January 1, 2027.
    • The policy applies to initial and continuation treatment of gMG when the applicable requirements are met.
    Step Therapy

    Required Prior Conventional Therapy

    Document inadequate response, intolerance, or contraindication to the required conventional therapies before requesting initial authorization. The required history varies by antibody status and product.

    • Epysqli, Ultomiris, and anti-AChR/anti-LRP4/triple-seronegative Vyvgart: an acetylcholinesterase inhibitor plus at least one immunosuppressive therapy, in combination or as monotherapy.
    • Anti-MuSK Vyvgart, Imaavy, and Rystiggo: at least one immunosuppressive therapy.
    • Examples include pyridostigmine or neostigmine; azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide.
    Documentation Required

    Rystiggo Prior-Therapy Requirement

    For Rystiggo requests, clearly document the required prior treatment history according to antibody status. Anti-AChR-positive individuals require an acetylcholinesterase inhibitor and at least one immunosuppressive therapy; anti-MuSK-positive individuals require at least one immunosuppressive therapy.

    • Document inadequate response, intolerance, or contraindication for each required prior therapy.
    • Therapies may have been used in combination or as monotherapy where specified.
    Documentation Required

    gMG Diagnosis and Severity Documentation

    Submit objective documentation of gMG diagnosis, disease severity, age, antibody status, and functional impairment for the requested product.

    • Epysqli and Ultomiris: age ≥18, MGFA class II–IV, anti-AChR positive, MG-ADL ≥6.
    • Vyvgart/Vyvgart Hytrulo: age ≥18, MGFA class II–IV, approved antibody status or triple-seronegative electrodiagnostic confirmation, MG-ADL ≥5.
    • Imaavy: age ≥12, MGFA class II–IVa, anti-AChR or anti-MuSK positive, MG-ADL ≥6.
    • Rystiggo: age ≥18, MGFA class II–IVa, anti-AChR or anti-MuSK positive, MG-ADL ≥3 with at least 3 non-ocular points.
    Documentation Required

    Prior Treatment History

    Include a complete treatment history showing the required conventional therapies and the outcome of each trial. State whether the individual had inadequate response, intolerance, or a contraindication.

    • Identify the acetylcholinesterase inhibitor and immunosuppressive agent(s), when required.
    • For antibody-specific requirements, identify the relevant anti-AChR, anti-MuSK, anti-LRP4, or triple-seronegative status.
    Documentation Required

    Meningococcal Vaccination and REMS

    Before initiating Epysqli or Ultomiris, document meningococcal vaccination and compliance with the applicable REMS requirements. Treatment may begin before the 2-week vaccination interval only when therapy cannot be delayed or the risk of delaying therapy outweighs infection risk.

    • Use current ACIP recommendations for individuals receiving complement inhibitors.
    • Document prescribing-physician REMS enrollment.
    Documentation Required

    Vyvgart Serology or Electrodiagnostic Confirmation

    For Vyvgart or Vyvgart Hytrulo, document an approved antibody finding or the required triple-seronegative electrodiagnostic confirmation.

    • Accepted serology: anti-AChR positive, anti-MuSK positive, or anti-LRP4 positive.
    • Triple-seronegative disease requires characteristic findings on repetitive nerve stimulation or single-fiber electromyography.
    Documentation Required

    Rystiggo Laboratory and Symptom Documentation

    For Rystiggo, submit the pretreatment IgG level and symptom documentation supporting the MG-ADL requirement.

    • IgG must be ≥5.5 g/L.
    • MG-ADL total score must be ≥3, with at least 3 points attributable to non-ocular symptoms.
    Documentation Required

    Continuation Response Documentation

    For reauthorization, document continued eligibility and a clinically meaningful response from the pretreatment baseline. Each product requires a decrease of 2 points in the MG-ADL total score; Imaavy also requires reduced signs or symptoms affecting daily function.

    • Epysqli, Ultomiris, Vyvgart/Vyvgart Hytrulo, and Rystiggo: 12-month reauthorization period.
    • Imaavy: 12-month reauthorization period with reduction in daily-function symptoms and a 2-point MG-ADL decrease.
    • Continuation requests must also show that the applicable initial-treatment criteria remain satisfied.
    Documentation Required

    REMS Documentation and Counseling

    For Epysqli or Ultomiris, the prescriber must complete the applicable REMS duties and provide required counseling and safety materials. Monitor for meningococcal infection and take the required action if infection is suspected or confirmed.

    • Enroll and certify through the REMS; assess vaccination status and revaccinate according to ACIP.
    • Provide the Patient Safety Card and Patient Safety Brochure; prescribe 2 weeks of antibiotic prophylaxis when therapy starts less than 2 weeks after vaccination.
    • Discontinue therapy during treatment of serious meningococcal infection and report meningococcal cases and outcomes to the manufacturer.
    Documentation Required

    Meningococcal Vaccination

    Document meningococcal vaccination in accordance with current ACIP recommendations before administering Epysqli or Ultomiris, unless delaying therapy presents greater risk.

    • Use both MenACWY and MenB vaccines for individuals receiving complement inhibitors.
    • MenACWY booster: every 5 years during therapy.
    • MenB booster: 1 year after series completion and then every 2–3 years during therapy.
    Documentation Required

    Document Antibody or Seronegative Status

    For updated Vyvgart criteria, the request must identify the individual's antibody status or provide electrodiagnostic confirmation of triple-seronegative disease. Do not rely solely on a general gMG diagnosis.

    • Document anti-AChR, anti-MuSK, or anti-LRP4 positivity, or triple-seronegative disease confirmed by RNS or single-fiber electromyography.
    • Anti-MuSK-positive requests require at least one qualifying immunosuppressive-therapy history.
    Denial Risk

    Prohibited Combination Therapy

    Do not request or administer any policy drug in combination with the prohibited maintenance immunoglobulin or biologic therapies listed for that product. Such combinations may result in denial.

    • Prohibited combinations across the products include maintenance immunoglobulin, eculizumab, ravulizumab-cwvz, efgartigimod, nipocalimab-aahu, rozanolixizumab-noli, zilucoplan, and rituximab, as applicable to the requested drug.
    • Verify the complete medication list before submission and treatment.
    Denial Risk

    Clinical Eligibility Criteria Not Met

    Requests may be denied when the documented clinical eligibility criteria are not met. Confirm the product-specific age, MGFA class, antibody or electrodiagnostic status, and MG-ADL threshold before submitting.

    • Epysqli and Ultomiris require age ≥18, MGFA class II–IV, anti-AChR positivity, and MG-ADL ≥6.
    • Vyvgart requires age ≥18, MGFA class II–IV, qualifying serology or electrodiagnostic confirmation, and MG-ADL ≥5.
    • Imaavy requires age ≥12, MGFA class II–IVa, anti-AChR or anti-MuSK positivity, and MG-ADL ≥6.
    • Rystiggo requires age ≥18, MGFA class II–IVa, anti-AChR or anti-MuSK positivity, and MG-ADL ≥3 with at least 3 non-ocular points.
    Denial Risk

    Required Vaccination or REMS Not Documented

    Failure to document required meningococcal vaccination, the applicable exception, or REMS enrollment may result in denial of Epysqli or Ultomiris authorization.

    • Document vaccination at least 2 weeks before the first dose unless treatment cannot be delayed.
    • Document appropriate REMS certification and enrollment for the prescribing physician.
    Denial Risk

    Other Indications Investigational

    Rozanolixizumab-noli is considered investigational for indications other than generalized myasthenia gravis meeting the policy criteria.

    • Rystiggo coverage is limited to qualifying gMG; other indications are not medically necessary under this policy.
    Denial Risk

    Active Infection

    Avoid administering efgartigimod alfa-fcab to an individual with an active infection. Evaluate infection status before treatment and before initiating a new treatment cycle.

    • Monitor during administration and for 1 hour afterward for hypersensitivity reactions.
    • Evaluate age-appropriate vaccination needs before a new treatment cycle.
    Billing Rule

    Incorrect Dosage Form

    Do not use the subcutaneous dosage form of ravulizumab-cwvz for generalized myasthenia gravis. gMG treatment requires the approved intravenous formulation and weight-based regimen.

    • 40 to <60 kg: 2,400-mg loading dose, then 3,000 mg every 8 weeks.
    • 60 to <100 kg: 2,700-mg loading dose, then 3,300 mg every 8 weeks.
    • ≥100 kg: 3,000-mg loading dose, then 3,600 mg every 8 weeks.
    • Administer by IV infusion through a 0.2- or 0.22-micron filter and monitor for at least 1 hour after infusion.
    MGFA Class I
    Class IAny ocular muscle weakness
    Eye closureMay include weakness of eye closure
    Other muscle strengthAll other muscle strength is normal
    MGFA Class II
    Class IIMild weakness affecting muscles other than ocular muscles, with or without ocular weakness
    Class IIaPredominantly affects limb muscles, axial muscles, or both; may include lesser oropharyngeal involvement
    Class IIbPredominantly affects oropharyngeal muscles, respiratory muscles, or both; may include lesser or equal limb or axial involvement
    MGFA Class III
    Class IIIModerate weakness affecting muscles other than ocular muscles, with or without ocular weakness
    Class IIIaPredominantly affects limb muscles, axial muscles, or both; may include lesser oropharyngeal involvement
    Class IIIbPredominantly affects oropharyngeal muscles, respiratory muscles, or both; may include lesser or equal limb or axial involvement
    MGFA Class IV
    Class IVSevere weakness affecting muscles other than ocular muscles, with or without ocular weakness
    Class IVaPredominantly affects limb muscles, axial muscles, or both; may include lesser oropharyngeal involvement
    Class IVbPredominantly affects oropharyngeal muscles, respiratory muscles, or both; may include lesser or equal limb or axial involvement
    MGFA Class V
    Class VDefined as intubation, with or without mechanical ventilation
    ExceptionExcludes intubation used during routine postoperative management
    Feeding tube without intubationClassified as IVb
    gMG serotypes
    Anti-AChR positiveAntibodies against the acetylcholine receptor are detectable
    Anti-MuSK positiveAntibodies may target muscle-specific receptor tyrosine kinase
    Anti-LRP4 positiveA recognized antibody group in generalized myasthenia gravis
    Triple-seronegativeNo detectable anti-AChR, anti-MuSK, or anti-LRP4 antibodies
    Abbreviations
    AChRAcetylcholine receptor
    Clinical relevanceAn antibody target associated with generalized myasthenia gravis
    Policy wordingAnti-AChR means antibody positive for the acetylcholine receptor
    Abbreviations
    gMGGeneralized myasthenia gravis
    Disease contextGeneralized form of myasthenia gravis
    Policy useThe diagnosis addressed by the biologic treatment criteria
    Abbreviations
    MG-ADLMyasthenia Gravis-Activities of Daily Living score
    Measure typePatient-reported functional assessment
    Policy useUsed to document impairment and treatment response
    Abbreviations
    QMGQuantitative Myasthenia Gravis score
    Measure typeClinical measure of disease severity
    Policy useUsed to assess treatment response
    Abbreviations
    NSISTsNonsteroidal immunosuppressive therapies
    Therapy typeImmunosuppressive treatment category
    Policy contextIncluded among prior conventional therapies considered before biologic treatment
    MG-ADL scale
    Full nameMyasthenia Gravis-Activities of Daily Living scale
    Assessment purposeAssesses activities-of-daily-living symptoms and treatment response
    Policy applicationUsed for baseline impairment and continuation response
    QMG measure
    Full nameQuantitative Myasthenia Gravis score
    Assessment purposeClinical measure of disease severity and treatment response
    Use in evidenceReported as an outcome measure in generalized myasthenia gravis trials
    gMG classification
    Full nameGeneralized myasthenia gravis
    Classification contextClassified using Myasthenia Gravis Foundation of America clinical classes
    Classes citedIIa/b, IIIa/b, or IVa/b